Stereotaxis appoints Ross Levin to its Board of Directors

– USA, MO – Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of directors. Mr. Levin is the Director of Research at Arbiter Partners, a successful New York-based investment fund and shareholder of Stereotaxis. Mr. Levin serves on the board of directors for NYSE-listed Capital Senior Living Corporation and is Vice Chairman of the Cerebral Palsy Associations of New York State.

“Stereotaxis has the potential to transform endovascular medicine and improve patient care,” said Mr. Levin. “I am excited to join the board and look forward to actively contributing to the effort to build a highly successful and impactful company.”

Concurrent with the appointment of Mr. Levin, Stereotaxis also announced that Fred A. Middleton is retiring from the board. Mr. Middleton and Sanderling Ventures were among the first institutional investors in Stereotaxis and Mr. Middleton has served on the board of directors since the company’s earliest days as a start-up. “I have enjoyed my time helping Stereotaxis grow from a promising new technology to a global company with clinically and commercially validated surgical robotic systems in cardiology that have successfully treated over 100,000 patients to date,” commented Mr. Middleton. “I am also encouraged by the commitment of Stereotaxis’ management and investors to the continued innovation of the Company’s technology platform which I believe should create a path for greater clinical adoption and growth.”

Chairman of the Board and CEO, David Fischel, remarked on the transition, “We appreciate Fred’s many contributions over the years in nurturing and supporting Stereotaxis’ progress. We are excited to have Ross join the board.”

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>